[A26-87] Benralizumab (hypereosinophilic syndrome) – Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2026
Project no.:
A26-87
Commission:
Commission awarded on 15.07.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adults and adolescents aged 12 years and older weighing at least 35kg with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A26-87
| Project no. | Title | Status |
|---|---|---|
| A18-11 | Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-113 | Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |